CTIS2024-514609-76-00进行中（未招募）1 期
SIRIUS Sarcoidosis with moderate to severe facial skin involvement: an open multicenter study of the efficacy and safety of oral sirolimus
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Age = 18 years < 75 years (men and wome, -Cutaneous sarcoidosis with facial involvement (diagnosed as follows: compatible clinical appearance showing brownish or yellowish erythematoviolet macules or papules or nodules and compatible histological appearance on either facial or extrafacial skin biopsy confirming the diagnosis of sarcoidosis showing epithelioid and gigantocellular granulomas without caseous necrosis) moderate to severe defined by: SASI (sarcoidosis area and severity index) facial score = 2 AND PGA (Physician's Global Assessment, scale 1 to 10) of skin = 5, Membership of a French health insurance scheme, - Patients who have failed at least one line of conventional systemic treatment, or who are naïve to systemic treatment., - For women of childbearing age (unless confirmed post-menopausal or sterile), pregnancy test with negative ßHCG. Effective contraception by contraceptive pill or intrauterine device must be used during treatment with Sirolimus and for 12 weeks after discontinuation of sirolimus., - Patients with written consent
排除标准
- •-Severe hepatic impairment (cytolysis (ALT) > 3N and/or cholestasis (PAL) > 3N), -Treatment with cyclins for less than 1 month, -Treatment with topical corticosteroids or tacrolimus for less than 1 week, -At least one organ affected by sarcoidosis requiring systemic treatment other than sirolimus (oral corticosteroid or systemic per os or parenteral immunosuppressive therapy), Cholesterolemia > 3 g/L or triglyceridemia > 4 g/L, -Concomitant administration of powerful CYP3A4 inhibitors or inducers such as rifampicin, ketoconazole, voriconazole, telithromcyine, diltiazem, verapamil, erythromycin, clarythromycin, ciclosporin., Pregnancy or breast-feeding, Active infection, including tuberculosis, Uncontrolled hypertension (SBP > 150 mmHg and/or DBP > 100 mmHg), - Patients under guardianship or trusteeship, persons deprived of their liberty, under court protection, under psychiatric care, under restraint, admitted to a health or social establishment for purposes other than those of research, -cancer patient (except basal cell carcinoma of the skin or cancer in situ of the uterine cervix), -Allergy or intolerance to sirolimus or any of its excipients, -Risk of poor patient compliance., -Use of grapefruit or grapefruit juice during treatment, - patients with fructose or galactose intolerance, glucose-galactose malabsorption, sucrase-isomaltase or Lapp lactase deficiency., Peanut or soy allergy, - Lung or liver transplant patients, -Treatment with general corticosteroids or immunosuppressive agents (methotrexate, azathioprine, mycophenolate mofetil, cyclophosphamide, cyclosporine) in the month preceding inclusion., Treatment with hydroxychloroquine in the month prior to inclusion, -Treatment with intralesional corticoids for less than 3 months, -Treatment with biotherapies (anti-TNFa, anti-IL12/23, anti-IL17A) in the 3 months prior to inclusion, -Treatment with thalidomide or other imides for less than 3 months
研究者
相似试验
尚未招募
2 期
Sirolimus in Cutaneous SarcoidosisCutaneous SarcoidosisSarcoidosisNCT05458492Assistance Publique - Hôpitaux de Paris10
进行中（未招募）
不适用
Sandostatin therapy in sarcoidosisSarcoidosisEUCTR2013-005376-17-NLErasmus Medical Center
已完成
2 期
Sandostatin therapy in sarcoidosisSarcoidosis10003816NL-OMON40194Erasmus MC, Universitair Medisch Centrum Rotterdam20
招募中
不适用
Sandostatin therapy in sarcoidosisSarcoidosis, sandostatinSarcoïdose, sandostatineNL-OMON25865Erasmus Medical Center, Department of Internal Medicine.20
已完成
不适用
Nuclear Magnetic Resonance Spectroscopic Analysis of Urinary Metabolome in Sarcoidosis (RMN-SARCURINES)SarcoidosisNCT05181930Assistance Publique - Hôpitaux de Paris42